

BIOENGINEERED SKIN FOR THE TREATMENT OF RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA

Results achieved from researches from CIBER, CIEMAT, UC3M and IIS-FJD have developed a novel procedure to treat patients with dystrophic epidermolysis bullosa

The need

Recessive dystrophic Epidermolysis bullosa (RDEB) is a subtype of DEB characterised by generalized cutaneous and mucosal blistering. RDEB is caused by loss-of-function mutations in the COL7A1 gene (C7).

C7 deficiency results in generalized blistering of the skin and other stratified epithelia, scarring, fibrosis, mitten-like deformities in hands and feet, and a high risk of developing metastatic squamous cell carcinoma.

The solution

The present medicinal product discloses and autologous bioengineered skin containing polyclonal populations of RDEB patient keratinocytes and fibroblasts corrected by a non-viral gene editing strategy.

The technology is based on genetic correction of keratinocytes and fibroblasts will allow expression of type VII collagen, C7, by both cell types leading, in turn, to anchoring fibril formation and restoration of dermal-epidermal adhesion.

Innovative aspects

- The use of a bioengineered skin containing fibroblasts and keratinocytes represents an advantage over single sheets of genetically corrected epidermal cells in terms of **handling** (mechanical resistance) and **resemblance of the native skin situation** where both cell types produce C7.
- The field of application of the invention is patients with RDEB who carry pathogenic mutations in exon 80 of the COL7A1 gene, but also this **technology could be useful for other exons of this gene**, being able to be effective for a larger number of RDEB patients.
- Bioengineered skin containing CRISPR/Cas9 gene-edited keratinocytes through a non-viral precise excision of exons encoding COL7A1 collagenous domain, is not authorized anywhere worldwide for the treatment of RDEB.
- The innovation of the present technology is based on the use of an **accuracy gene-correction method** (edition instead of addition) of extremely high efficiency that allows the **immediate application of corrected cells** without selection of edited cell clones.
- Furthermore, another key point is the use of a **non-viral gene transfer system** instead of using a viral vector which has potential risks associated with their genomic integration.

Stage of Development:

IMPD enabling apply for a Phase I/II clinical trial

IP status:

Orphan Drug Designation

Aims

Looking for a partner interested in a license and/or a collaboration agreement to develop and exploit this asset.

Contact details